EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Aclaris Therapeutics EBITDA Margin % Related Terms
Aclaris Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Aclaris Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACRS vs IMMX, PRME, CLYM: EBITDA Margin % Comparison
For the Biotechnology subindustry, Aclaris Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aclaris Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aclaris Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aclaris Therapeutics (ACRS) has a EBITDA Margin % of -1,106.71% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aclaris Therapeutics and its competitors. According to the industry distribution chart, Aclaris Therapeutics ranks #746 out of 945 companies in the Biotechnology industry, placing it in the top 78.9%.
Is Aclaris Therapeutics' EBITDA Margin % too high?
Aclaris Therapeutics' current EBITDA Margin % is -1,106.71%. Based on the distribution chart, Aclaris Therapeutics ranks #746 out of 945 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Aclaris Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aclaris Therapeutics' EBITDA Margin % compare to IMMX and PRME?
According to the Biotechnology industry distribution chart, Aclaris Therapeutics ranks #746 out of 945 companies for EBITDA Margin %. This places Aclaris Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Aclaris Therapeutics and its competitors. Aclaris Therapeutics's current EBITDA Margin % is -1,106.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aclaris Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aclaris Therapeutics (ACRS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.45, compared to a current price of $4.95 — trading 998.9% above its estimated fair value. The current EBITDA Margin % is -1,106.71%. Aclaris Therapeutics' overall GF Score™ is 38/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Aclaris Therapeutics (ACRS), the current EBITDA Margin % is -1,106.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aclaris Therapeutics (ACRS) Overvalued in 2026?
Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued.
The current stock price of $4.95 is trading 998.9% above its estimated GF Value™ of $0.45.
GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.
Key valuation signals for ACRS:
EBITDA Margin %: -1,106.71%
GF Value™: $0.45 vs. price of $4.95 (998.9% above fair value)
No single metric tells the full story. See the ACRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
38GF Score
Get the complete analysis for ACRS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRS has been successfully added to your 
